ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SIGA vs KROS // EV/EBITDA & P/E VALUATION

SIGA Technologies Inc. (NASDAQ) VS. Keros Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SIGA 2 — KROS 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SIGA VS. KROS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SIGA KROS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 68.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 42.70% 85.00% -42.30 KROS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 4.8x — — TIE /valuation <GO>
Free Cash Flow Yield 19.03% — — TIE /fcf-yield <GO>
Operating Margin 25.10% 27.70% -2.60 KROS /operating-margins <GO>
Net Profit Margin 24.60% 35.70% -11.10 KROS /net-margins <GO>
Revenue Growth (YoY) -31.80% 180.00% -211.80 KROS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.22 4.31 +3.91 SIGA /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 KROS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.7 40.6 -3.88 KROS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 9.1x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $228.5M $225.2M $3.2M SIGA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SIGA REV KROS REV SIGA GROSS % KROS GROSS % SIGA FCF KROS FCF
FY 2025 $94.6M $244.1M 68.6% — $43.5M $106.0M
FY 2024 $138.7M $3.5M 77.4% — $48.8M -$162.8M
FY 2023 $139.9M $151.0K — — $94.8M -$124.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SIGA // BETA —
KROS // BETA —